Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH9A4S)

• Drug Name: ADS-103253 Drug Info
• Synonyms: ADS-103253; CHEMBL216228; SCHEMBL6507329; BDBM50200788

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11452268
  TTD Drug ID: DMH9A4S

Molecule-Related Drug Atlas

Drug(s) Targeting Melanin-concentrating hormone receptor 1 (MCHR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-830216	DMCW71N	Obesity	5B81	Phase 1	[2]
AZD1979	DMQ1OX4	Obesity	5B81	Phase 1	[3]
PMID25522065-Compound-27	DMXN4KB	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-29	DMBNAK9	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-34	DMZDIRQ	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-39	DM5YMQH	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-40	DMCIQ01	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-11	DM410Z6	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-50	DMBWA0V	N. A.	N. A.	Patented	[4]
PMID25522065-Compound-12	DMVKO9C	N. A.	N. A.	Patented	[4]

Drug(s) Targeting Voltage-gated potassium channel Kv11.1 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VESNARINONE	DMBKX3C	Cardiac failure	BD10-BD13	Approved	[5]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[6]
HP-184	DMNOMV2	Multiple sclerosis	8A40	Phase 2	[7]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[8]
ABT-229	DMN3S1B	Pain	MG30-MG3Z	Phase 2	[9]
ISOQUINE	DMR17YI	Malaria	1F40-1F45	Phase 1	[10]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[11]
Isoindoline derivative 5	DMIUTQW	N. A.	N. A.	Patented	[12]
Isoindoline derivative 3	DM2MYL9	N. A.	N. A.	Patented	[12]
Isoindoline derivative 4	DMP1NKI	N. A.	N. A.	Patented	[12]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[13]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[14]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[15]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[16]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[17]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[18]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[19]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[19]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[19]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Inhibitor	[1]
Melanin-concentrating hormone receptor 1 (MCHR1)	TTX4RTB	MCHR1_HUMAN	Inhibitor	[1]
Voltage-gated potassium channel Kv11.1 (KCNH2)	TTQ6VDM	KCNH2_HUMAN	Inhibitor	[1]

References

• [1] Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7.
• [2] 2011 Pipeline of Bristol-Myers Squibb.
• [3] Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc
• [4] Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207.
• [5] Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.
• [6] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [7] Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
• [8] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [9] 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8.
• [10] Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
• [11] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
• [12] The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
• [13] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [14] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [15] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [16] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [17] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [18] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [19] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.